Seiji Kishi, MD, PhD, FACP

Nephrologist 高知大学医学部教授

[Seiji Kishi, MD, PhD, FACP @nephroendoscopy]

@hama_nephro すぐだと思います。

[医療統計start-upサロン @tokei389950]

京都大学医学研究科が公開している
「大学生のための統計学入門」が
めちゃくちゃ有益。

https://t.co/gsFytyBhEL

臨床統計家育成コース向けの内容ですが、
文系・理系を問わず学べるように
分かりやすく整理されています。

しかも、動画と講義資料の両方が
公開されているのもオススメポイント。

統計を学び始めた人や、
基礎をもう一度整理したい人には
かなりおすすめです。

[Seiji Kishi, MD, PhD, FACP @nephroendoscopy]

@YuyaMatsue 同意です！

[Seiji Kishi, MD, PhD, FACP @nephroendoscopy]

@ono_cardiology 引き続きご指導お願いいたします！

[Seiji Kishi, MD, PhD, FACP @nephroendoscopy]

@naka_takaya すぐに課金リミットが来ると思って使わず。でした。

[Seiji Kishi, MD, PhD, FACP @nephroendoscopy]

@naka_takaya Totally agree with you

[NDT @NDTsocial]

Cyclosporin A- versus tacrolimus-specific lesions in calcineurin inhibitor nephrotoxicity

📖https://t.co/YqWY38PW3c

[Seiji Kishi, MD, PhD, FACP @nephroendoscopy]

@Ryu04196650Ryu だからこそ、臨床しっかりやらねばですよね。

[宇津 貴史 /Utsu, Takashi @Office_j]

【雑記】

日本循環器学会は「糖代謝異常者における循環器病の診断・予防・治療に関するコンセンサスステートメント2026」も無料公開。

https://t.co/sZlNKQxlY0

[NDT @NDTsocial]

IDF Diabetes Atlas 11th edition 2025:

global prevalence and projections for 2050

https://t.co/OYyBLNPZ7p

[Abdelhamed Hamdy @Abdelhamed6261]

#ERA26
UACR/PCR earlier is better
kidney filter quality and speed not the same

[かずなり | 生成AI活用術 @MacopeninSUTABA]

筑波大学が公開した「Python入門」が有益すぎる。

全300ページ超の圧倒的ボリュームで、基本文法からクラス、オブジェクト指向の概念まで徹底解説。単にコードをなぞるのではなく、プログラミングの本質的な考え方が身につく構成。最高のバイブル。

こちら👉
https://t.co/XfNIVVPsyI

[joslerの犬（柿の葉寿司） @wankosobanyan]

ほんと過去問見る前は内科専門医のちょっと発展バージョンくらいかと思ってたんだけど、内科専門医のクエバンやら何やら一通り勉強し終えた僕が過去問見ても１ミリも分からないレベルでした😇 チラッとしか見てないけど内科専門医と総合内科専門医は高校入試と大学入試くらいレベル違うんじゃないかと

[Abdelhamed Hamdy @Abdelhamed6261]

#ERA26
personalized treatment for MN

[joslerの犬（柿の葉寿司） @wankosobanyan]

医師免許を持ったビジネスマンやタレントとか色々いるけど医師免許を持ってるだけで「医者」とは言えんと思う。医学は単なる資格ではなく歩み続ける「道」。毎日患者と向き合って勉強して、時に悩んで、教わったり教えたり、そして何よりJOSLERの160の症例登録と29の病歴要約を終えた人が医者

[Ahmed Bennis MD 🫀 @drbennisahmed]

Real-world evidence from LEGEND-T2DM (JACC 2026):
GLP-1RAs ≈ SGLT2is for CV outcomes at the ingredient level in 1.2M T2DM patients on metformin across 10 global databases.

Guideline flexibility supported — choose based on comparative safety profiles, not CV efficacy alone.

[Abdelhamed Hamdy @Abdelhamed6261]

#ERA26
Rituximab in MCD/FSGS

[Dr Danish @operationdanish]

🤯 JUST IN: INCREDIBLE PHASE 3 DATA ON RETATRUTIDE PRESENTED AT ADA

At ADA this weekend, Eli Lilly ($LLY ) presented new Phase 3 data from TRIUMPH-1 and TRANSCEND-T2D-1. BLUF: 28% (70 pounds) weight loss. Unreal.

In TRIUMPH-1, participants receiving 12 mg of retatrutide lost an average of 70.3 pounds (28.3%) over 80 weeks. Nearly half achieved at least 30% weight loss, and 65.3% were no longer classified as obese (BMI <30) by the end of the study. Among participants who started with BMI ��35 and continued treatment to 104 weeks, average weight loss reached 85 pounds (30.3%), with no evidence that weight loss had fully plateaued.

What stood out more was the breadth of effect across obesity-related conditions:

Knee osteoarthritis pain improved by 73.1%
Obstructive sleep apnea severity improved by 60.6%
Triglycerides fell by as much as 41.0%
Non-HDL cholesterol declined by 24.2%
Systolic blood pressure dropped by 12.3 mmHg
Waist circumference decreased by 9.5 inches

Meanwhile, in TRANSCEND-T2D-1, retatrutide produced A1C reductions of up to 2.0% from a baseline of 7.9%.

90% of patients achieved A1C <7%
85% achieved A1C ≤6.5%
46% reached A1C <5.7%, which is below the threshold used to define prediabetes
Patients lost 36.6 pounds (16.8%) at 40 weeks, and weight loss was still ongoing at study end.

Obesity medicine is increasingly becoming outcomes medicine.

Historically, we have evaluated obesity drugs primarily on percent weight loss... but payers ultimately care about sleep apnea, osteoarthritis, diabetes, cardiovascular risk, and healthcare costs.

The significance of TRIUMPH-1 and TRANSCEND-T2D-1 is that Lilly is beginning to show a coherent story across those endpoints, not just body weight. I expect this to expand coverage dramatically.

Eli Lilly is the Nvidia of healthcare.